Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-1 axicabtagene ciloleucel in refractory aggressive B-cell non-Hodgkin lymphoma
NL-OMON54771Phase 2Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- May 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of axicabtagene ciloleucel in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 2 more (3 arms), sponsored by Kite Pharma. Primary endpoints: Incidence of dose-limiting toxicities, Objective response rate and 1 more. Started May 2017; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)large-cell lymphoma
Beyond the preview
Go deeper on NL-OMON54771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54771.